No Data
No Data
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) Adds CN¥440m in Market Cap and Insiders Have a 38% Stake in That Gain
Key Insights Significant insider control over Hunan Fangsheng Pharmaceutical implies vested interests in company growth A total of 6 investors have a majority stake in the company with 52% ownership
Fangsheng Pharmaceutical (603998.SH): Net profit of 70.19 million yuan in the first quarter increased 10.04% year-on-year
On April 19, Ge Longhui Pharmaceutical (603998.SH) released its first quarter report. Operating revenue was 438 million yuan, up 0.37% year on year, net profit of 70.19 million yuan, up 10.04% year on year, after deducting non-net profit of 53.8976 million yuan, up 9.61% year on year, with basic earnings of 0.16 yuan per share.
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 10% over the past month, it is easy to disregard Hunan Fangsheng Pharmaceutical (SHSE:603998). However, stock prices are usually driven by a company's financial performance over
Fangsheng Pharma's Factories Pass GMP Inspection
Hunan Fangsheng Pharmaceutical's (SHA:603998) production lines passed the good manufacturing practice or GMP inspection of China's National Medical Products Administration in Hunan province, the pharm
Fangsheng Pharmaceutical (603998.SH) passed the drug GMP compliance inspection
Fangsheng Pharmaceutical (603998.SH) issued an announcement. The company received the “Drug G...” issued by the Hunan Drug Administration
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March
Hunan Fangsheng Pharmaceutical (SHA:603998) obtained government subsidies worth 12.1 million yuan between January and March, the company said in its disclosure on the Shanghai Stock Exchange. The bene
No Data